Related Experiment Video
Updated: Mar 30, 2026
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
Platelet - derived CD154 antigen in patients with chronic kidney disease
Joanna Stępniewska1, Barbara Dołęgowska2, Marta Chruściana2
1Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland.
Insights
Renal replacement therapy affects platelet activation markers, soluble CD154 (sCD154) and soluble CD40 (sCD40). Hemodialysis significantly increased sCD40 in platelet-rich plasma, correlating with lipid levels in chronic kidney disease patients.
Area of Science:
- Immunology
- Nephrology
- Cardiovascular Medicine
Background:
- CD154, a glycoprotein on activated immune cells, mediates cell-to-cell communication and inflammation.
- Soluble CD154 (sCD154) and soluble CD40 (sCD40) levels are prognostic markers for cardiovascular complications.
- Chronic kidney disease (CKD) involves metabolic disorders, inflammation, and oxidative stress, potentially altering sCD154/sCD40 balance.
Purpose of the Study:
- To analyze sCD154 and sCD40 concentrations in platelet-rich plasma (PRP) and platelet-poor plasma (PPP).
- To investigate the influence of different renal replacement therapies (conservative, hemodialysis, peritoneal dialysis) on these markers in CKD patients.
Main Methods:
- Examined 141 CKD patients: pre-dialysis (n=68), hemodialysis (n=38), and peritoneal dialysis (n=35).
- Quantified sCD154 and sCD40 using ELISA.
- Assessed biochemical parameters via colorimetric methods.
Main Results:
- Significant differences in sCD154 and sCD40 concentrations were observed based on renal replacement therapy.
- Hemodialysis led to a significant increase in sCD40 within PRP.
- sCD40 and sCD154 levels showed correlations with lipid parameters.
Conclusions:
- The type of renal replacement therapy impacts platelet activation in CKD patients.
- Altered platelet activation may contribute to the heightened risk of cardiovascular complications in CKD.
Introduction:
CD154 is a surface glycoprotein present on activated platelets, lymphocytes and mast cells. It mediates the transmission of information between cells and initiates an inflammatory response. The interaction of CD154 with its receptor CD40 leads to increase in concentrations of soluble forms of both molecules (sCD154, sCD40), which has an important prognostic value in cardiovascular complications. The metabolic disorders in chronic kidney disease (CKD), chronic inflammation, increased oxidative stress and type of renal replacement therapy may influence on the balance of sCD154/sCD40 in plasma and blood platelets. The purpose of the reasearch was to analyse the concentrations of sCD154 antigen and sCD40 receptor in platelet pure plasma (PPP) and platelet rich plasma (PRP) of patients with CKD treated conservatively, haemodialysed and on petitoneal dialysis.
Methods:
The group examined comprised 141 patients with chronic kidney disease: in pre-dialysis stage (n = 68), haemodialysed (n = 38) and on peritoneal dialysis (n = 35). The concentrations of sCD154 and sCD40 in PRP and PPP were determined with an ELISA method. The biochemical parameters were obtained using colorimetric method.
Results:
The concentrations of sCD154 and sCD40 in PPP and PRP in examined group were significantly different depending on the method of renal replacement therapy. The haemodialysis procedure caused a significant increase in sCD40 concentration in PRP. The concentrations of sCD40 and sCD154 were correlated with lipid parameters.
Conclusions:
The type of renal replacement therapy influences on platelet activation which may be a factor contributing to increased cardiovascular complications in patients suffering from CKD.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:28Chronic Kidney Disease III: Interprofessional Care
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention